Cancer medicine prices: what NPPA’s 30% margin cap could change
The regulator has approved a wider cap in principle. A drug list and notification will determine which medicines and prices it covers.
India’s drug-price regulator approved a wider cap on cancer-medicine trade margins in principle on 8 October 2026. The National Pharmaceutical Pricing Authority (NPPA) proposes to limit those margins to 30% of the maximum retail price, or MRP, for selected medicines outside the usual ceiling-price list.
The next step is to identify the medicines. An expert committee under the Directorate General of Health Services (DGHS) has been asked to recommend the list by 14 October. NPPA will then take a decision and issue a notification. For anyone buying a medicine, the list and notification will establish which products and prices the reform covers. The signed NPPA meeting minutes record both the approval and its conditions.
Why some medicines already have ceiling prices
India’s medicine-price rules distinguish between scheduled and non-scheduled formulations. Scheduled formulations appear in the first schedule of the Drugs (Prices Control) Order, 2013, and are subject to government-set ceiling prices. A formulation is the medicine in a particular form and strength, rather than just the name of an ingredient.
Non-scheduled medicines sit outside that ceiling-price system. They still face price regulation: the order ordinarily limits increases in their MRP to 10% over the preceding twelve months. An annual increase limit constrains how quickly a price can rise, but does little to reduce a price that starts high.
The proposed intervention uses a different tool: limiting the margin added along the supply chain. NPPA is invoking Paragraph 19 of the price-control order, which gives it powers to fix ceiling or retail prices in extraordinary circumstances in the public interest. “Non-scheduled” describes a pricing category; it does not describe a medicine’s effectiveness.
What “30% of MRP” means
A trade margin is the spread between prices at different points in the supply chain. The crucial detail in this proposal is its denominator: the cap is expressed as a share of the final MRP.
Suppose an MRP is ₹100. Thirty per cent of it is ₹30, leaving ₹70 as the other portion. The same ₹30 is about 42.9% of ₹70. Percentages change when the denominator changes.
| Illustrative arithmetic | Amount |
|---|---|
| Final MRP | ₹100 |
| 30% of that MRP | ₹30 |
| Other 70% | ₹70 |
This example explains the percentage. The ₹70 is not manufacturing cost or manufacturer profit; the notification still needs to set out the pricing details. Any reduction in an existing MRP will depend on the margin already built into it, rather than being a uniform 30% price cut.
Why a lower MRP and a lower bill can differ
NPPA’s minutes identify high trade mark-ups as a contributor to expensive cancer medicines. They also record substantial differences between transaction prices in retail pharmacies, hospitals and online pharmacies, including the discounts offered from MRP.
This makes the printed maximum price and the price a patient currently pays two different starting points. A buyer paying the full MRP has more to gain from a lower maximum than someone already receiving a large discount on the same pack. The effect on an actual bill depends on the revised MRP and the seller’s resulting price.
The measure concerns selected medicines. Hospital services, diagnostic tests and other parts of treatment remain separate costs.
The projected savings have a precedent
NPPA estimates that the proposed exercise could reduce covered medicines’ MRPs by roughly 20–70%, depending on their existing trade structure, and yield around ₹2,500 crore in annual savings. These are the authority’s expectations for the new intervention.
The precedent comes from February 2019, when NPPA applied trade-margin rationalisation to 42 selected non-scheduled cancer drugs. The government subsequently reported reductions across 526 brands and annual savings of ₹984 crore. That earlier exercise helps explain why the government is returning to this approach; its reported outcomes are separate from the new estimates.
The 8 October announcement says the intended coverage spans branded and generic, domestic and imported, and patented and non-patented medicines. It also says manufacturers will be required to maintain current production levels, pairing the affordability intervention with an availability requirement.
The list and notification are the next milestones
The requested 14 October committee report is a step towards selecting the drugs, rather than an announced date when pharmacy prices change. After that, NPPA’s notification should make it possible to check the covered formulation, strength and pack against the applicable price and effective date.
The useful question then becomes concrete: what is the new price for the exact medicine pack being purchased, compared with the price currently paid? That comparison will show how the proposed margin limit reaches a patient’s bill.